Published in Lancet on March 27, 1993
Evaluation of clinical utility of serum enzymes and troponin-T in the early stages of acute myocardial infarction. Indian J Clin Biochem (2003) 0.79
[Biomarker for diagnosis of rejection after heart transplantation]. Herz (2010) 0.75
Cardiac troponin T. Lancet (1993) 2.13
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet (2000) 4.54
Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation (2003) 4.48
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 4.15
Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol (1997) 3.64
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation (2002) 3.22
Side effects of long-term amiodarone therapy. Circulation (1983) 3.03
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet (2001) 3.02
Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.97
Fatal overdosage with disopyramide. Lancet (1978) 2.96
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Smoking and decreased fertilisation rates in vitro. Lancet (1992) 2.92
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol (2000) 2.89
Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol (1990) 2.67
Cardiac fatigue following prolonged endurance exercise of differing distances. Med Sci Sports Exerc (2000) 2.47
Purchasing 'legal highs' on the Internet--is there consistency in what you get? QJM (2010) 2.43
Amiodarone pharmacokinetics. Am Heart J (1983) 2.42
Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol (1983) 2.34
Electrocardiographic changes in 1000 highly trained junior elite athletes. Br J Sports Med (1999) 2.32
Expression of inducible nitric oxide synthase in human heart failure. Circulation (1996) 2.26
Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J (1999) 2.24
Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart (2004) 2.22
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J (1985) 2.22
Comparison of two strategies for myocardial management during coronary artery operations. Ann Thorac Surg (1994) 2.21
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J (1997) 2.16
Measuring brain natriuretic peptide. Lancet (1996) 2.03
Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol (1998) 2.03
Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart (2007) 1.97
Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J (1981) 1.91
Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol (1990) 1.91
N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J (2003) 1.87
High-density substrate mapping in Brugada syndrome: combined role of conduction and repolarization heterogeneities in arrhythmogenesis. Circulation (2009) 1.83
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation (1999) 1.76
Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol (2001) 1.74
Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation (1990) 1.73
M mode echocardiography in hypertrophic cardiomyopathy: diagnostic criteria and prediction of obstruction. Am J Cardiol (1980) 1.72
Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol (1999) 1.71
Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest (1994) 1.69
Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol (1993) 1.68
Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart (2000) 1.66
Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. J Am Coll Cardiol (1992) 1.66
Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation (2001) 1.64
QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J (1996) 1.63
Clinical significance of giant negative T waves in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.60
Evaluation of fetal arrhythmias by echocardiography. Br Heart J (1983) 1.59
Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg (1995) 1.58
Homozygous mutation of desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair. Cardiology (2008) 1.57
Mechanisms of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol (1992) 1.57
Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. Eur Heart J (2001) 1.54
Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation (1997) 1.48
Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine. Ther Drug Monit (1997) 1.48
TGF-beta quantitation can be tricky. Transplantation (1999) 1.47
Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment. Br Heart J (1981) 1.46
Q waves in hypertrophic cardiomyopathy in relation to the distribution and severity of right and left ventricular hypertrophy. J Am Coll Cardiol (1990) 1.45
Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart (1999) 1.45
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation (1999) 1.44
Ventricular tachycardia of left bundle branch block configuration in patients with isolated right ventricular dilatation. Clinical and electrophysiological features. Br Heart J (1984) 1.42
Reflex responses of venous capacitance vessels in patients with hypertrophic cardiomyopathy. Clin Sci (Lond) (1998) 1.41
Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm. Br Heart J (1988) 1.41
Side effects and possible contraindications of amiodarone use. Am Heart J (1983) 1.40
Pulmonary amyloidosis occurring after heart transplantation for amyloid heart disease. J Heart Lung Transplant (1995) 1.40
Human chagasic disease is not associated with an antiheart humoral response. Am J Cardiol (1997) 1.40
A simple approach to risk stratification in adult heart transplantation. Eur J Cardiothorac Surg (1999) 1.40
Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur Heart J (1996) 1.39
Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation (1992) 1.38
A controlled trial of substrate-enhanced, warm reperfusion ("hot shot") versus simple reperfusion. Ann Thorac Surg (2000) 1.38
Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation (1992) 1.38
Familial dilated cardiomyopathy in the United Kingdom. Br Heart J (1995) 1.37
The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med (2009) 1.36
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J (1999) 1.36
Amiodarone therapy during pregnancy. Am J Cardiol (1983) 1.35
Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol (1997) 1.32
Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation (1998) 1.31
High-performance liquid chromatographic measurement of amiodarone and its desethyl metabolite: methodology and preliminary observations. Ther Drug Monit (1982) 1.31
Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol (1980) 1.30
Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child (1984) 1.29
Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J (1999) 1.29
Cardiomyopathy mutations reveal variable region of myosin converter as major element of cross-bridge compliance. Biophys J (2009) 1.28
Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol (2000) 1.28
Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol (2000) 1.27
Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol (1984) 1.26
Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum. J Chromatogr (1981) 1.26
A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation (2000) 1.26
Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy. J Am Coll Cardiol (1995) 1.24
Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart (2005) 1.24
Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart (2005) 1.24
Paediatric use of mexiletine and disopyramide. Br Med J (1979) 1.23
Amiodarone in testis and semen. Lancet (1985) 1.20
Buying 'legal' recreational drugs does not mean that you are not breaking the law. QJM (2010) 1.19
Signal-averaged electrocardiography in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.18
Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation (1997) 1.18
Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit (2001) 1.17
A common mitochondrial DNA variant associated with susceptibility to dilated cardiomyopathy in two different populations. Lancet (2001) 1.17
Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics. Circulation (1995) 1.17
Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart (2008) 1.17